The hardware and bandwidth for this mirror is donated by METANET, the Webhosting and Full Service-Cloud Provider.
If you wish to report a bug, or if you are interested in having us mirror your free-software or open-source project, please feel free to contact us at mirror[@]metanet.ch.
SMMAL is an R package for estimating the Average Treatment Effect (ATE) using semi-supervised learning (SSL), tailored for settings with limited treatment/outcome labels but rich covariates and surrogate variables. It enhances efficiency and robustness over supervised methods by leveraging unlabeled data and supports high-dimensional models via cross-fitting, flexible model fitting, and adaptive LASSO.
# install.packages("devtools")
devtools::install_github("ShuhengKong/SMMAL")A github version can be found at this link: https://github.com/ShuhengKong/SMMAL
This is a basic example which shows you how to solve a common problem:
library(SMMAL)
# Load the example dataset included with the package
file_path <- system.file("extdata", "sample_data.rds", package = "SMMAL")
dat <- readRDS(file_path)
temp <- data.frame(dat$X)
temp[,] <- NA
# Estimate ATE using the SMMAL pipeline
output <- SMMAL(
Y = dat$Y,
A = dat$A,
S = data.frame(dat$S),
X = data.frame(dat$X),
nfold = 5,
cf_model = "bspline"
)
# View the results
print(output)
#> $est
#> [1] 0.1021349
#>
#> $se
#> [1] 0.03006258| Column | Description |
|---|---|
| Y | Observed outcomes. Can be continuous or binary |
| A | Treatment indicator. Must be binary |
| S | Surrogates |
| X | Covariates |
| nfold | Number of cross-validation folds. Default is 5. |
| cf_model | The modeling method to use in cross-fitting. Default is “bspline”. Other values are “xgboost”,“randomforest” |
| custom_model_fun | Optional user-supplied function for feature selection or prediction. Overrides the built-in model fitting. Must return fold-level predictions. |
| Column | Description |
|---|---|
| est | estimated value of ATE |
| se | standard error of ATE |
These binaries (installable software) and packages are in development.
They may not be fully stable and should be used with caution. We make no claims about them.